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Abstract
Live attenuated Salmonella spp. are promising candidates as oral vaccine delivery systems for heterologous antigens. Clinical trials have
demonstrated that this approach is feasible for human vaccinations but further optimisation is necessary to obtain a better efficacy. Here,
we discuss how existing clinical and pre-clinical data can be used to guide such optimisation efforts. ß 2000 Federation of European
Microbiological Societies. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Vaccines o¡er e⁄cient, cost-e¡ective measures against
widespread infectious diseases. Among the various deliv-
ery systems, orally administered live attenuated Salmonella
spp. that express heterologous antigens are promising can-
didates as they are safe and highly immunogenic and can
elicit long-lasting protective systemic and mucosal immune
responses against the heterologous pathogen [1^7]. As an
example, it was recently shown that the Salmonella-based
approach is highly e⁄cacious in an animal infection model
of the important human pathogen Helicobacter pylori
[8,9].
Despite the great success of Salmonella-based heterolo-
gous vaccination in various animal models, it remains a
challenge to adopt this promising approach to human ap-
plications. In this review, we summarise the results ob-
tained in human heterologous vaccination trials and dis-
cuss recent developments which can help to develop
e⁄cacious human vaccines based on live recombinant Sal-
monella.
2. Small animal vaccination model
All human trials with Salmonella as carriers conducted
so far have used attenuated strains of the human-adapted
serovar Salmonella typhi, the causative agent of typhoid
fever. In humans, this serovar is systemically infective, and
attenuated vaccines of S. typhi can elicit both mucosal and
systemic immune responses.
Mice are the most widely used pre-clinical model for
vaccination studies. S. typhi does not cause a systemic
infection in mice under physiological conditions but mice
can be infected with the mouse-adapted serovar Salmo-
nella typhimurium which causes a systemic, typhoid-like
syndrome that mimics the human disease caused by
S. typhi.
A major concern is the safety of live attenuated carriers
of heterologous antigens. To generate safe carrier strains,
de¢ned genetic lesions are introduced into speci¢c genes of
a virulent wild-type isolate, rendering it highly attenuated.
The close resemblance of the mouse S. typhimurium model
to the human S. typhi situation makes it possible to ¢rst
de¢ne appropriate attenuations in the mouse S. typhimu-
rium model [10^14] and then to introduce analogous mu-
tations into S. typhi strains for human trials (see below).
Correlation of attenuations in both systems has been suc-
cessfully demonstrated for several speci¢c mutations in-
cluding the genes aroA, aroC, aroD, htrA, cya, crp, cdt,
and phoPQ.
Live vaccines should be safe also in immuno-compro-
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mised vaccinees. Various attenuated Salmonella strains
have been tested in transgenic mice with de¢ned defects
in their immune system to assure that their attenuations
are safe even if the immune response directed against the
vaccine strain is impaired [15^20]. The relevance of these
observations for human vaccination is underscored by re-
cent ¢ndings that patients with genetic IL-12p40 [21] or
IL-12 receptor de¢ciencies [22,23] exhibit strongly in-
creased susceptibility to disseminated infection with non-
typhoid Salmonella.
Based on the detailed mouse data and the human trials
using prototype heterologous Salmonella vaccines, it is
now possible to discuss various aspects concerning the
construction of a second generation of improved Salmo-
nella carriers for human use. Important parameters for
this strain construction are the choice of the Salmonella
serovar, the particular genetic background of the carrier,
the type of attenuating lesions and the expression system
for the foreign antigen.
3. Salmonella serovar
In various animal models, both host-adapted and non-
host-adapted serovars have been successfully used. In hu-
mans, however, only derivatives of the human-adapted
serovar S. typhi have been tested so far although there is
no principle reason not to try other Salmonella serovars.
In particular for pathogens that are restricted to mucosal
surfaces like H. pylori, the mucosal immune response eli-
cited in humans by enteritic Salmonella serovars (e.g. en-
teritidis, typhimurium) could be su⁄cient to confer protec-
tion. Such enteric serovars are especially attractive as their
wild-types cause much less severe disease in humans. As a
consequence, less severe attenuations might be su⁄cient to
prevent unwanted side e¡ects which enhances the chance
to retain immunogenicity (see below). In a recent primate
example using an enteric serovar, rhesus macaques have
successfully been vaccinated using attenuated S. typhimu-
rium expressing an SIV antigen [26].
4. Genetic background
The genetic background of the vaccine carrier strain can
signi¢cantly in£uence the immune response. For example,
in the mouse model, two S. typhimurium strains that carry
identical attenuations but have been derived from di¡erent
isolates elicit signi¢cantly di¡erent serum IgG and mu-
cosal IgA antibody responses against a heterologous anti-
gen [24]. In humans, identically constructed S. typhi aroC
aroD deletion strains that have been derived from di¡erent
isolates induce signi¢cantly di¡erent immune responses
[16] which con¢rm and extend the mouse data.
Interestingly, all human trials for heterologous vaccina-
tion have used carrier strains that had been derived from a
single S. typhi isolate (Ty2) that has been cultured in the
laboratory since its isolation in 1916.
5. Attenuations
A prerequisite for the use of live recombinant Salmonel-
la for vaccination is a su⁄cient attenuation to prevent
unwanted side e¡ects like bacteremia, diarrhoea or fever.
On the other hand, over-attenuation can lead to poor
immunogenicity of the vaccine, indicating that a delicate
balance between attenuation and over-attenuation must be
maintained.
Mouse data indicate that various independent genetic
defects can yield adequately attenuated Salmonella strains.
Among strains that are attenuated to similar levels, the
speci¢c type of attenuation can strongly in£uence the im-
mune response [27^29], adding further complexity to the
choice of the attenuating mutations. Human live vaccine
strains should carry at least two independently attenuating
mutations to minimise the hypothetical risk of reversion to
virulence by DNA transfer from wild-type organisms in
the ¢eld. Deletion is the preferred type of attenuating mu-
tation as compared to point mutations that can spontane-
ously revert to wild-type. Except for the S. typhi Ty800
strain which carries an attenuating mutation at a single
chromosomal locus (phoPQ) [30], all strains that have
been tested in humans so far ful¢l both criteria.
6. Strains that have been used in human vaccine trials
Table 1 summarises comparable results from phase I
clinical trials with various heterologous S. typhi vaccines.
For a comparison, clinical results obtained for S. typhi
strains that do not express heterologous antigens are
shown in Table 2.
6.1. Ty21a
The chemically induced S. typhi mutant Ty21a is char-
acterised by mutations in the galactose biodegradation
pathway including galE [31], and an inability to synthesise
the Vi capsular antigen. However, these defects do not
account for the safety of Ty21a, since a genetically de¢ned
site-directed galE mutant which is also Vi negative retains
its virulence in human volunteers [32]. Therefore, the mu-
tations that cause the attenuation of Ty21a remain unde-
¢ned. Ty21a has been given as an anti-typhoid vaccine to
more than 327 000 subjects world-wide in several con-
trolled e⁄cacy trials (recently reviewed in [33]). The strain
is very well tolerated even at doses of 1011 orally applied
living organisms [34], and pooled results from ¢ve clinical
toxicity studies involving some 700 subjects of all age
groups showed very few adverse reactions in vaccinees
(2% fever and vomiting, and some 5% mild diarrhoea)
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[33]. Depending on the vaccine formulation and the coun-
try where the study was performed, Ty21a exhibited be-
tween 33% and 96% protective e⁄cacy, and protection
lasted for at least 4 years [33]. However, the vaccine has
a low immunogenicity and requires 3^4 oral doses to
achieve optimal protection [35,36].
In addition to its world-wide use as an anti-typhoid
vaccine, S. typhi Ty21a has also been used as a carrier
for heterologous antigens [37^40]. Lipopolysaccharides
(LPS) from Shigella were introduced into Ty21a via trans-
fer of a 120-MDa Shigella plasmid which likely expressed
additional Shigella protein antigens. Administration of
three doses of this S. typhi^Shigella bivalent vaccine re-
sulted in 50^70% protection against Shigella-induced
bloody diarrhoea in human volunteer challenge studies
[41]. Protection correlated with the presence of Shigella
LPS-speci¢c serum IgA and IgG levels prior to challenge
[41], while no correlation was observed between protection
and the frequency of Shigella-speci¢c antibody-secreting
cells (ASC), which were detected in all vaccinees [42]. Un-
fortunately, several subsequently prepared lots of the vac-
cine including a large scale lyophilised preparation were
entirely ine¡ective [41,43], perhaps owing to frequent re-
arrangements of the LPS-encoding Shigella plasmid in Sal-
monella [44].
To construct a bivalent typhoid^cholera vaccine, Vibrio
cholerae LPS biosynthesis genes were expressed in S. typhi
Ty21a from a thyA-stabilised plasmid (see below). Small
Table 1
Vaccine strain
(background)
Mutation Heterologous antigen Vaccination
regimen
Immune responses to
heterologous antigen
% Vaccine
e⁄cacy
(protected
vaccinees)
Refer-
ence
% Ig
res-
ponsea
% ASC
(IgA)
ASC/106
PBMs
CD8
CTL
5076-1C (Ty21a) Several Shigella sonnei O antigen
(+120-MDa plasmid)
Oral, V109
(3U)
21^35 100 10 n.d. 53^71 [41^
43,68]
EX645 (Ty21a) Several V. cholerae O antigen Oral, V1010
(3U)
7^43 7 n.d. n.d. 25 [38,40]
M4632 [pYA3167] (Ty2) cya, crp^cdt,
asd/asd
Hepatitis B core pre-S
fusion on asd plasmid
Oral, 107^109 0 0 0 n.d. n.d. [46]
M4632 [pYA3167] (Ty2) cya, crp^cdt,
asd/asd
Hepatitis B core pre-S
fusion on asd plasmid
Oral, rectal,
108^109 (3U)
17 n.d. n.d. n.d. n.d. [48]
CVD908 6(varoC : :tacP-
rcsp) (Ty2)
aroC, aroD P. falciparum circum-
sporozoite protein
CSP21ÿ398, inserted into
aroC, tac promoter
5U107 (2U) 20 n.d. n.d. 10 n.d. [53]
n.d. : not determined.
aSummary of all serological parameters including serum IgA and IgG and local IgA as well as bactericidal antibodies.
Table 2
Comparison of clinical data for S. typhi human vaccines
Strain Mutation Oral
dosea
Reacto-
genicity
Bactere-
mia
With
diarrhoea
(%)b
With rise in
serum IgG
(%)c
With ASC
(IgA) in PBM
(%)
ASC
(IgA)/106
PBM
Refer-
ence
Ty21a Multiple 1010 (4U) None ? None 63 60^80 n.d. [54]
M3927 cya, crp 5U105 Some 17 n.d. 33 50 n.d. [25]
M4073 cya, crp^cdt 5U108 None 0 20d 80 80 15 [46]
M4632
[pYA3167]
cya, crp^cdt, asd/asd 3U108 Some n.d. Several 43 n.d. n.d. [48]
CVD906 aroC, aroD 5U107 Some 56 0 89 100 1750 [25]
CVD906-htrA aroC, aroD, htrA 5U108 None 0 13 75 100 80 [52]
CVD908 aroC, aroD 5U108 Some 100 0 100 100 1060 [25,52]
CVD908-htrA aroC, aroD, htrA 5U108 None 0 13 100 100 120 [52]
Ty800 phoPQ 5U108 None 0 0 100 100 830 [30]
Ty445 phoPQ, aroA 1010 (2U) None 0 10 14 n.d. n.d. [54]
n.d. : not determined.
aSingle oral dose unless otherwise noted.
bTrials involved between three and 14 vaccinees.
cS. typhi-speci¢c serum IgG against somatic and/or £agellar antigen.
dAt a dose of 5U107.
FEMSIM 1192 13-3-00
D. Bumann et al. / FEMS Immunology and Medical Microbiology 27 (2000) 357^364 359
Downloaded from https://academic.oup.com/femspd/article-abstract/27/4/357/520896
by WWZ Bibliothek (Oeffentliche Bibliotherk der UniversitÃ¤t Basel) user
on 27 November 2017
scale clinical trials demonstrated sero-conversion against
V. cholerae LPS in 7^43% of human vaccinees by at least
one of several parameters, and the vaccine protected 25%
of volunteers from challenge with virulent V. cholerae,
with the additional positive e¡ect that diarrhoea in non-
protected subjects was much milder than in unvaccinated
controls [38,40].
6.2. M4073 and M4632
S. typhi Ty21a has been followed by a second genera-
tion of S. typhi vaccine strains that carry de¢ned genetic
lesions. In S. typhi M3927 vcya vcrp, deletions in the reg-
ulatory cya (adenylate cyclase) and crp (cyclic AMP recep-
tor protein) genes a¡ect the expression of a large variety of
genes including carbon, phosphate and nitrogen metabo-
lism, pH regulation, iron uptake, ¢mbria and £agella bio-
synthesis, and cause reduced growth rates and cell sizes in
vitro [45]. This strain retains some reactogenicity (eliciting
of adverse side e¡ects) in human vaccinees [25], and has
therefore been further attenuated by an additional deletion
extending from the crp gene to the cdt gene, the latter
being required for the colonisation of deep tissues in
mice [12]. The resulting strain M4073 was well tolerated
in doses up to 5U108 orally applied colony forming units
(cfu) in humans [46]. For a stable and high expression of
heterologous antigens using a balanced^lethal system (see
below), an additional mutation in asdA1 has been intro-
duced to obtain S. typhi M4632 [47].
Hepatitis B virus (HBV) pre-S envelope proteins S1 and
S2, fused to the HBV core protein (HBc-pre-S), have been
expressed as heterologous protein antigens in S. typhi
M4632 [46,47]. HBc-pre-S is constitutively and stably ex-
pressed in vitro at s 1% of total cellular protein from a
pBR-based, asd-stabilised plasmid (see below). No sero-
response to this heterologous antigen was elicited in hu-
mans after a single oral dose in a study at the Center for
Vaccine Development in Baltimore, MD, USA [46]. A
similar study using the same vaccine was performed at
the Centre Hospitalier Universitaire Vaudois, Lausanne,
Switzerland, with the exception that the vaccine was ap-
plied in three doses, spaced by several weeks, and was
given orally or rectally to female volunteers only [48].
Out of six rectally immunised volunteers, only one sero-
converted against the pre-S1 antigen. This individual was
the only one that sero-converted against S. typhi LPS and
in addition su¡ered from severe and prolonged diarrhoea,
suggesting a possible link between severity of reaction to
the vaccine and its immunogenicity. None of seven orally
immunised subjects sero-converted against pre-S1 [48].
6.3. CVD908 and CVD908-htrA
The strain S. typhi CVD908 carries two independent
deletions (aroC and aroD) in the common aromatic bio-
synthesis pathway [49]. The mutations cause an obligate
requirement for para-aminobenzoic acid (PABA), which is
present in only limiting amounts in host tissues relevant to
infection. PABA is an intermediate in the synthesis of
folate, which in turn functions as a cofactor in the major-
ity of one-carbon transfer reactions, including the formu-
lation of the translational initiator fMet-tRNAfMet [50].
Thus, the ultimate inability to initiate protein biosynthesis
after depletion of an intracellular pool of folate has been
speculated to account for both the initial replication of
various aro mutants in host tissues as well as their subse-
quent growth arrest [51]. In severely immunode¢cient
mice, however, aroA mutants have recently been shown
to be virulent [15,16], indicating that aro mutant strains
can replicate in host tissues. Possibly, replication is not
fast enough to prevent the elimination by a functional
host immune system whereas even slow bacterial growth
could not be controlled in severely immunode¢cient hosts.
An insu⁄cient attenuation by aro mutations was also
observed in human trials in which the strain S. typhi
CVD908 varoC varoD was found to cause unacceptably
high levels of silent bacteremia in healthy volunteers. To
further attenuate this strain, an additional mutation was
introduced in the htrA gene that encodes a periplasmic
serine protease [13] to obtain CVD908-htrA, which is
save and immunogenic in humans [52].
A truncated version of the Plasmodium falciparum pro-
tein CSP has been constitutively expressed in S. typhi
CVD908 by chromosomal integration of the csp gene
into its already mutated aroC locus. Two oral doses of
5U107 cfu resulted in sero-conversion in two out of 10
vaccinees, while a third vaccinee developed antigen-speci¢c
CD8 cytolytic activity [53]. To our knowledge, no data
for heterologous vaccination using the improved carrier
strain CVD908-htrA have yet been reported.
6.4. Ty800 and Ty800-aroA
The S. typhi strain Ty800 carries a deletion in the
phoPQ two component global virulence gene regulatory
system. This strain is safe and highly immunogenic in hu-
mans as indicated by high frequencies of antigen-speci¢c
ASC [30]. An additional deletion in aroA leads to an ob-
ligate requirement for PABA (see above) which over-at-
tenuates the resulting strain Ty800-aroA, rendering it only
poorly immunogenic even at multiple high doses [54].
To our knowledge, no data for the strain S. typhi Ty800
as a carrier for foreign antigens in human trials have yet
been reported.
7. Antigen expression
The expression level of foreign antigen can strongly in-
£uence the immune response that is induced by live re-
combinant Salmonella spp. (e.g. [24]). The desired high
heterologous expression for a su⁄cient amount of time
FEMSIM 1192 13-3-00
D. Bumann et al. / FEMS Immunology and Medical Microbiology 27 (2000) 357^364360
Downloaded from https://academic.oup.com/femspd/article-abstract/27/4/357/520896
by WWZ Bibliothek (Oeffentliche Bibliotherk der UniversitÃ¤t Basel) user
on 27 November 2017
is often hampered by the rapid in vivo loss of plasmids
encoding foreign antigens [55].
Integration of the foreign gene into the Salmonella chro-
mosome has been successfully used to obtain recombinant
strains that very stably express heterologous antigens. In
the case of S. typhi CVD908, chromosomal insertion of
the heterologous gene csp leads to expression levels high
enough to elicit some human immune responses against
this foreign antigen (see Table 1) [53].
Because of the low copy number, the amount of heter-
ologous antigen that can be expressed from the genes
integrated into the Salmonella chromosome is usually
smaller as compared to plasmid-based expression. An al-
ternative for increasing the stability of expression at higher
copy numbers is to use a balanced^lethal system in which
a lethal chromosomal mutation is complemented by a
plasmid that carries both a functional copy of the same
gene and an expression cassette for the foreign antigen. In
one such system, a mutation in the chromosomal aspartate
L-semialdehyde dehydrogenase (asd) gene leads to an ob-
ligate requirement for diaminopimelic acid, which can be
complemented by a plasmid carrying a functional copy of
the Salmonella asd gene [56,57]. In another balanced^lethal
system, thymidine requirement caused by a mutation in
the chromosomal thymidylate synthetase (thyA) gene is
complemented by a plasmid carrying a functional thyA
gene [58]. Both systems allow for a stable, high expression
of foreign antigens in recombinant Salmonella strains and
have been used with some success in human vaccine trials
[38,40,46,48]. In addition, both systems provide the addi-
tional advantage that no antibiotic resistance marker is
required for the selection of transformed bacteria. This is
an important aspect as antibiotic resistance markers are
not acceptable for constructs to be used in human vacci-
nation trials.
8. Conclusions
The results obtained for the various S. typhi prototype
carriers and expression systems demonstrate the general
feasibility of human vaccination with live Salmonella ex-
pressing foreign antigens. The results summarised in Table
2 demonstrate the general correlation between the patho-
genic potential (reactogenicity and the ability to cause
bacteremia) and the immunogenicity of the vaccine.
Thus, the highly attenuated S. typhi Ty21a is poorly im-
munogenic. For the strains S. typhi M3927, CVD906,
CVD908 and Ty800, the introduction of additional attenu-
ating mutations reduced both the reactogenicity and im-
munogenicity. The ability to induce mild diarrhoea ap-
pears to be a frequent problem with the S. typhi-based
live vaccine strains.
Despite some success in human trials, the immune re-
sponses induced by live Salmonella expressing foreign anti-
gens are weaker than those observed for analogous con-
structs in various animal models. It should be noted that
with the exception of one trial (S. typhi CVD908 express-
ing CSP), only humoral responses but not the important
cell-mediated immune responses against the heterologous
antigen were monitored. Depending on the pathogen and
the appropriate correlate of protection, measuring just
antibody responses can considerable underestimate the ef-
¢cacy of a vaccine as has been demonstrated, for example,
for rhesus macaques receiving Salmonella expressing an
antigen from SIV [26]. Nevertheless, further improvement
of the immunogenicity of Salmonella-based vaccines for
human use seems to be necessary. Based on the human
trials and the extensive experience gained in the mouse
system, a number of options for such an improvement
exist.
As all human heterologous vaccination studies have
used strains derived from a single isolate of only one se-
rovar, the use of other Salmonella serovars and/or isolates
might be an obvious option to get better carrier strains.
Unfortunately, it seems to be di⁄cult to predict the im-
munogenicity of a new isolate based on pre-clinical data.
Hence, empirical testing in human trials would be neces-
sary to obtain better carrier strains.
Only a limited set of attenuating mutations have been
tested in the human trials. In the mouse model, several
new mutations have been identi¢ed that yield safe strains
with superior immunogenicity as compared to the com-
monly used aro strains. More such mutations are likely
to be found in the future. Some of these mutations could
be interesting candidates to be tested in carriers for human
use.
Additional innovative approaches that were developed
using animal models and have yet not been tested in hu-
man trials include the use of the two-phase variation sys-
tem for the expression of antigens that are toxic to Sal-
monella [59,60], presentation of the antigen in di¡erent
compartments of the bacteria or the infected host cell
[61,62,68], co-expression of immuno-modulatory mole-
cules [63^66]), and the use of in vivo inducible promoters
to achieve localised high level expression of the foreign
antigen [55,67]. These new approaches illustrate the great
potential for improvement of live attenuated Salmonella
spp. as vaccine delivery systems for e⁄cacious and cost-
e¡ective human vaccination.
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